
usd may pm et
summari compani distributor pharmaceut medical-surg suppli
relat product broad rang health care custom
nm price-to-earnings oper ep
drug medic suppli distribut oper
strong long-term sale growth prospect view due
develop popul age increas health care
util expand global middl class gain
access advanc medicin barrier entri
industri also high three firm control
 drug distribut posit
balanc limit price power due larg scale
consolid custom vertic integr
medic devic manufactur also present greater
oper litig risk pure distributor
view
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
inc lower
target fy jun ep
estim histor forward price-to-earnings
averag due margin contract rais
fy ep estim
maintain fy mar-q ep vs
beat consensu materi drop
tax rate mask yoy drop
led yoy growth
revenu off-set yoy
drop medic think organ
sale growth drug distribut
fastest peer strong top
line translat higher oper
earn drug distribut margin
continu rapidli contract
peer held
margin roughli flat yoy mar-q think
poor margin trend partial due
rel low mix profit specialti
need stabil share
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug specialti drug oncolog
infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut center
focus medic oper canada europ asia
oper margin gener higher medic fy saw medic oper margin versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx recent extend june
market profil increas access health insur especi global middl class expand
well age popul develop nation posit demand driver health care distribut
long term view drug price inflat deflat howev one critic
factor drug distribut profit short term return wareh logist inventori
data servic larg distribut contract typic pay distributor negoti percentag
purchas order amount price often negoti drug manufactur downstream
custom rise drug price therefor lead larger whole dollar servic fee distributor inflat
also help distributor tradit resal arrang purchas bulk inventori
manufactur resel downstream custom see profit rise lower-cost exist
inventori sold new higher price
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market
share addit gener drug sourc joint ventur larg retail pharmaci
becom standard began collabor jv improv bargain power
gener manufactur set similar jv walgreen
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut view pharmaceut sale growth slow
last year slower growth tradit drug busi led distributor seek higher growth
margin relat busi specialti pharmaceut medic suppli
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop healthcar provid
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori cordi signific drag earn growth due oper
problem inventori write-down mount litig cost help fuel goodwil
impair medic segment fiscal
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
financi trend total revenu increas billion billion
repres three-year compound annual growth rate compound-annual-growth-rate revenu growth boost
sever acquisit period howev adjust pre-tax incom per share account
capit oper cost acquisit fallen
three-year compound-annual-growth-rate neg drop incom driven steep declin oper
margin period leverag moder view adjust oper incom
cover net interest expens healthi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral driven mix posit
neg factor posit side
expect distribut revenu receiv
tailwind growth prescript drug
volum fda novel drug approv
neg side think profit margin
continu pressur integr
consolid drug suppli chain
focu mainli drug distribut
busi gener sale
health care distribut sub-industri
prescript drug demand like increas
view drive
higher drug volum handl distributor
believ primari factor rise drug
demand age babi boomer
prime health care util year gain
 health-insur popul
accord forb approxim
babi boomer turn everi day
latest year data avail censu
gov age cohort grew nearli
fast total popul expect
growth lead increas prescript
drug demand senior tend health
care need younger cohort
addit recent censu gov
data indic
health-insur popul continu grow
million individu ad health
plan view peopl health
insur like prescript
written fill uninsur due
manag drug cost insur
expect growth health-insur
popul continu year ahead
strong labor market pull peopl
care distributor also experi
benefit rise fda approv novel
new drug increas
significantli
market limit competit
allow attract price result
tailwind distributor fee
typic set percentag shipment
invoic valu receiv pharmaci
unfortun distributor expect
posit factor outlin
negat import headwind
see sub-industri declin price
power player drug suppli
chain becom power believ
distribut fee greatli impact drug
price negoti occur
pharmaci benefit manag pbm drug
maker well scale major
pharmaci chain receiv shipment
distributor view
integr pbm health insur
increas price power drug
maker lead declin net drug price
lower fee distributor trend
continu combin
aetna
express script expect major
pharmaci chain walgreen
continu consolid
retail pharmaci industri lead
greater bargain power
distributor suppli
year-to-d april
gain
declin
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain hold opinion share inc
lower target fy jun
ep estim histor forward price-to-earnings averag due margin
contract rais fy ep estim maintain fy
mar-q ep vs beat consensu materi drop
tax rate mask yoy drop pre-tax incom mar-q revenu
grew yoy led yoy growth pharmaceut revenu
off-set yoy drop medic think organ sale
growth drug distribut fastest peer strong
top line translat higher oper earn drug distribut
margin continu rapidli contract peer
held margin roughli flat yoy mar-q think poor
margin trend partial due rel low mix profit
specialti drug distribut busi think margin need stabil
share outperform /colin scarola
buy hold style text-align justifi target
impli ev/ebitda multipl ebitda discount five-year
averag multipl competitor reflect issu medic
segment keep jun ep estim lower ep
estim view record-high fda drug approv
potenti driver ep growth support guidanc cah largest
custom health corpor store retail
prescript volum growth think recent sell-off relat
may exagger cnbc report april
would shelv health care distribut effort due difficulti
win sticki hospit custom complex infrastructur
regul drug amzn subsequ june acquisit mail-ord retail
pharmaci neutral view pharmaci custom drug
distributor competitor /colin scarola
et cfra maintain hold opinion share inc
keep target fy jun
ep estim -- discount histor forward price-to-earnings averag
expect continu margin contract keep fy ep estim
lower fy dec-q ep vs
ahead consensu driven higher-than-expect revenu dec-q sale
yoy mark three straight quarter impress sale gain
driven higher volum lower sale price rise raw
materi cost continu pressur margin gross margin bp yoy
effici initi appear gain traction though
sg expens yoy overal adjust pre-tax incom flat
yoy per share basi rose reduc share count
yoy aggress repurchas share appear cheap trail
earn continu concern lack price power
et cfra keep hold opinion share cardin inc
lower target price-to-earnings near
low end rang fy jun ep estim
see valuat hurt weak medic segment organ trend
unfavor drug price inflat environ cut fy ep estim
mar-q adjust ep vs
estim neg tax impact weaker cordi result revenu
growth line expect pharmaceut segment sale
slightli expect growth exist custom
specialti drug off-set recent loss prime therapeut
contract pharmaceut margin continu pressur low inflat
recent acquisit weaker expect continu challeng
cardiolog endovascular suppli busi cordi see
continu fy /joseph agnes
et cfra keep hold opinion share cardin inc
rais target ep
estim discount histor averag forward price-to-earnings
signific headwind earn keep fy jun ep
estim lower sept-q ep vs
ahead consensu gener strongest quarter
revenu growth two year yoy estim adjust pre-tax incom
versu prior year period gross margin materi worsen
sg appear rise faster sale gener deflat
pharma segment revenue rise raw materi cost medic
segment drove drop gross margin quarter
year appear cheap trail earn continu
concern path stabil oper earn expect
sever gener deflat continu along rise cost
et cfra lower opinion cardin inc share
hold strong buy drop target
use ev/ebitda multipl materi discount five-year averag
competitor due headwind medic segment target reduc
due lower ebitda forecast drop fy jun ep estim
initi jun-q ep vs beat
consensu below-the-lin item yoy ebitda growth
big miss mainli driven primari pharma segment
expect modest margin declin roughli line competitor yet
bp drop jun-q pharma margin far worst drug
distributor caus lose drug margin lead reduc view
abil navig contract renew maintain earn
previous like valuat saw less-domin medic larger
risk view chang due pharma margin pressur particularli
largest custom must renew fy /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
